Catherine Le Berre
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Catherine Le Berre has a total of 199 co-authors. Here are the top co-authors by number of shared publications:
Arnaud Bourreille
Institut des Maladies de L'appareil Digestif (IMAD), Hépato‐Gastro‐Entérologie et Assistance Nutritionnelle, Inserm CIC 1413 Nantes Université, CHU Nantes Nantes France
8 shared publications- Arnaud Bourreille
Nantes Université, Institut des Maladies de l’Appareil Digestif, CHU de Nantes, CIC Inserm 1413 Nantes France
6 shared publications - Laurent Peyrin-Biroulet
Northwestern Medicine, Digestive Health Institute, Chicago, IL 60611, USA
5 shared publications - Anthony Buisson
Service d’Hépato-Gastroentérologie, CHU Clermont-Ferrand, Inserm, 3iHP, Université Clermont Auvergne, Clermont-Ferrand, France
4 shared publications Caroline Trang-Poisson
Institut des Maladies de l’Appareil Digestif, Hépato-Gastro-Entérologie et Assistance Nutritionnelle, Inserm CIC 1413, Nantes Université, CHU Nantes, Nantes, France
4 shared publicationsLaurent Peyrin-Biroulet
Department of Gastroenterology and Inserm NGERE U1256, University Hospital of Nancy, University of Lorraine, Vandoeuvre-lès-Nancy, France
4 shared publications
Latest Publications
- 23 September 2026
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
Revisiting the role of lymphatics in Crohn’s disease
Background: Early pathological observations consistently highlighted the involvement of the intestinal lymphatic system in Crohn’s disease (CD), although this remains underappreciated in current conceptual models of disease pathogenesis. This narrative review synthesizes evidence supporting lymphatic dysfunction as a key contributor of CD pathogenesis, and discusses its therapeutic potential. Methods: We searched PubMed to identify relevant studies on lymphatic biology in CD, including pathological, clinical, and experimental data. Results: Lymphatic obstruction, lymphangitis, and lymphangiectasia are early, widespread features of CD; structural remodeling coexists with compensatory lymphangiogenesis, suggesting a bidirectional relationship in which lymphatic dysfunction both drives and is sustained by intestinal inflammation. Peyer’s patches, closely integrated with the lymphatic network, may represent a portal of entry for luminal pathogens. CD susceptibility genes impair microbial handling at this interface, potentially enabling translocation into the lymphatics, endothelial injury, and the granulomatous lymphangitis hallmark of CD. Experimental models reinforce this framework: pathogens such as Yersinia or norovirus can induce lymphangitis preceding overt intestinal inflammation. Metastatic cutaneous CD, a rare extraintestinal manifestation involving lymphatic vessels characterized by granulomatous dermal inflammation at sites anatomically discontinuous from the gut, may provide a unique window into lymphatic pathology independent of the intestinal microbiome. Conclusions: These observations support an alternative view of CD in which intestinal lymphatic dysfunction plays an under-recognized role in both promoting and sustaining inflammation. This framework may explain disease features (patchy distribution, transmural inflammation, mesenteric hypertrophy) and positions the lymphatic system as a therapeutic target to restore drainage and modulate immune-lymphatic crosstalk.
- 23 September 2026
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
Revisiting the role of lymphatics in Crohn’s disease
Background: Early pathological observations consistently highlighted the involvement of the intestinal lymphatic system in Crohn’s disease (CD), although this remains underappreciated in current conceptual models of disease pathogenesis. This narrative review synthesizes evidence supporting lymphatic dysfunction as a key contributor of CD pathogenesis, and discusses its therapeutic potential. Methods: We searched PubMed to identify relevant studies on lymphatic biology in CD, including pathological, clinical, and experimental data. Results: Lymphatic obstruction, lymphangitis, and lymphangiectasia are early, widespread features of CD; structural remodeling coexists with compensatory lymphangiogenesis, suggesting a bidirectional relationship in which lymphatic dysfunction both drives and is sustained by intestinal inflammation. Peyer’s patches, closely integrated with the lymphatic network, may represent a portal of entry for luminal pathogens. CD susceptibility genes impair microbial handling at this interface, potentially enabling translocation into the lymphatics, endothelial injury, and the granulomatous lymphangitis hallmark of CD. Experimental models reinforce this framework: pathogens such as Yersinia or norovirus can induce lymphangitis preceding overt intestinal inflammation. Metastatic cutaneous CD, a rare extraintestinal manifestation involving lymphatic vessels characterized by granulomatous dermal inflammation at sites anatomically discontinuous from the gut, may provide a unique window into lymphatic pathology independent of the intestinal microbiome. Conclusions: These observations support an alternative view of CD in which intestinal lymphatic dysfunction plays an under-recognized role in both promoting and sustaining inflammation. This framework may explain disease features (patchy distribution, transmural inflammation, mesenteric hypertrophy) and positions the lymphatic system as a therapeutic target to restore drainage and modulate immune-lymphatic crosstalk.
- Open Access
- 9 June 2026
- Published by Wiley in United European Gastroenterology Journal
- Vol. 14 (5) , e70242
Artificial Intelligence Versus Conventional Scoring for Assessing Small Bowel Capsule Endoscopy Cleanliness in Crohn's Disease
Background and Aims: Evaluation of cleanliness in capsule endoscopy is essential to validate the exam. However, reliable evaluation of bowel cleanliness remains challenging. The validated KODA score provides robust assessment but is time‐consuming and impractical in routine practice. We aimed to evaluate the performance of an AI‐based tool (AXAROlite, Augmented Endoscopy) compared with the KODA score for assessing small bowel cleanliness in CD patients. Methods: This was a post hoc analysis of a multicenter randomized controlled trial (NCT05117996) including 142 CD patients undergoing SBCE after either a standard PEG‐based or simplified clear liquid preparation. All videos were evaluated for cleanliness using the KODA score by trained readers. The same videos were analyzed using the AI‐based AXAROlite tool. Correlation, agreement, and diagnostic performance of AXAROlite were compared with the KODA score. Clinical factors influencing AI‐assessed cleanliness were also investigated. Results: AXAROlite and KODA showed strong correlation for whole small bowel ( ρ = 0.61; p < 0.001). AXAROlite demonstrated excellent diagnostic accuracy for detecting adequate cleanliness defined as KODA > 2.25 (AUROC = 0.85, 95% CI 0.79–0.92), with an optimal threshold of 72% clean frames (sensitivity 86%, specificity 72%). Mean cleanliness decreased progressively from proximal to distal small bowel with both methods ( p = 0.001). The AXROlite score was independently reduced in patients with active disease and a longer small bowel transit time. Conclusions: AXAROlite provides a rapid, fully automated, and accurate evaluation of small bowel cleanliness in CD, comparable to the validated KODA score. Its integration into routine workflows may streamline reporting and reduce inter‐observer variability.
- 9 June 2026
- Published by Wiley in United European Gastroenterology Journal
- Vol. 14 (5) , e70242
Open AccessArtificial Intelligence Versus Conventional Scoring for Assessing Small Bowel Capsule Endoscopy Cleanliness in Crohn's Disease
Background and Aims: Evaluation of cleanliness in capsule endoscopy is essential to validate the exam. However, reliable evaluation of bowel cleanliness remains challenging. The validated KODA score provides robust assessment but is time‐consuming and impractical in routine practice. We aimed to evaluate the performance of an AI‐based tool (AXAROlite, Augmented Endoscopy) compared with the KODA score for assessing small bowel cleanliness in CD patients. Methods: This was a post hoc analysis of a multicenter randomized controlled trial (NCT05117996) including 142 CD patients undergoing SBCE after either a standard PEG‐based or simplified clear liquid preparation. All videos were evaluated for cleanliness using the KODA score by trained readers. The same videos were analyzed using the AI‐based AXAROlite tool. Correlation, agreement, and diagnostic performance of AXAROlite were compared with the KODA score. Clinical factors influencing AI‐assessed cleanliness were also investigated. Results: AXAROlite and KODA showed strong correlation for whole small bowel ( ρ = 0.61; p < 0.001). AXAROlite demonstrated excellent diagnostic accuracy for detecting adequate cleanliness defined as KODA > 2.25 (AUROC = 0.85, 95% CI 0.79–0.92), with an optimal threshold of 72% clean frames (sensitivity 86%, specificity 72%). Mean cleanliness decreased progressively from proximal to distal small bowel with both methods ( p = 0.001). The AXROlite score was independently reduced in patients with active disease and a longer small bowel transit time. Conclusions: AXAROlite provides a rapid, fully automated, and accurate evaluation of small bowel cleanliness in CD, comparable to the validated KODA score. Its integration into routine workflows may streamline reporting and reduce inter‐observer variability.
- 9 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Impact des interactions Cellules Gliales Entériques-Lymphocytes T dans le développement de la maladie de Crohn
La maladie de Crohn (MC) est caractérisée par une inflammation transmurale chronique de la paroi intestinale, induisant sa destruction progressive et irréversible. Malgré les avancées thérapeutiques, plus de 50 % des patients nécessitent à terme une intervention chirurgicale. La récidive post-opératoire (RPO) est quasiment inévitable, avec des stratégies de prévention peu efficaces. L'observation de plexites myentériques à la marge proximale de résection iléocolique a été reconnue comme un facteur de risque de RPO précoce, mais les mécanismes impliqués étaient inexplorés. Les objectifs de cette thèse étaient de caractériser la nature des cellules en interaction dans le plexus myentérique de patients atteints de MC, d'identifier les mécanismes moléculaires impliqués dans l'adhésion intercellulaire, et d'étudier l'impact des contacts neuro-immuns sur la production cytokinique afin d'identifier les molécules impliquées dans ces régulations. Les lymphocytes T (LT) adhèrent préférentiellement aux cellules gliales entériques (CGE) chez les patients atteints de MC, et la sévérité des plexites est associée à la RPO. Par des expériences de co-culture, nous avons montré que cette adhésion est augmentée par l'activation des LT et l'exposition de la glie à un environnement inflammatoire via l'expression d'ICAM-1. Les deux types de LT CD4+ et CD8+ sont en contact avec les CGE dans les plexites, et ces interactions augmentent la survie des LT de manière indépendante d'ICAM-1/LFA-1. Enfin, nous avons mis en évidence le rôle potentiel de PD-L1 dans la fonctionnalité des plexites myentériques, suggérant qu'un blocage de la voie ICAM-1/LFA-1 et/ou une restauration de la boucle PD-1/PD-L1 pourraient constituer des stratégies thérapeutiques prometteuses pour prévenir ou traiter la RPO dans la MC.
- 9 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Impact des interactions Cellules Gliales Entériques-Lymphocytes T dans le développement de la maladie de Crohn
La maladie de Crohn (MC) est caractérisée par une inflammation transmurale chronique de la paroi intestinale, induisant sa destruction progressive et irréversible. Malgré les avancées thérapeutiques, plus de 50 % des patients nécessitent à terme une intervention chirurgicale. La récidive post-opératoire (RPO) est quasiment inévitable, avec des stratégies de prévention peu efficaces. L'observation de plexites myentériques à la marge proximale de résection iléocolique a été reconnue comme un facteur de risque de RPO précoce, mais les mécanismes impliqués étaient inexplorés. Les objectifs de cette thèse étaient de caractériser la nature des cellules en interaction dans le plexus myentérique de patients atteints de MC, d'identifier les mécanismes moléculaires impliqués dans l'adhésion intercellulaire, et d'étudier l'impact des contacts neuro-immuns sur la production cytokinique afin d'identifier les molécules impliquées dans ces régulations. Les lymphocytes T (LT) adhèrent préférentiellement aux cellules gliales entériques (CGE) chez les patients atteints de MC, et la sévérité des plexites est associée à la RPO. Par des expériences de co-culture, nous avons montré que cette adhésion est augmentée par l'activation des LT et l'exposition de la glie à un environnement inflammatoire via l'expression d'ICAM-1. Les deux types de LT CD4+ et CD8+ sont en contact avec les CGE dans les plexites, et ces interactions augmentent la survie des LT de manière indépendante d'ICAM-1/LFA-1. Enfin, nous avons mis en évidence le rôle potentiel de PD-L1 dans la fonctionnalité des plexites myentériques, suggérant qu'un blocage de la voie ICAM-1/LFA-1 et/ou une restauration de la boucle PD-1/PD-L1 pourraient constituer des stratégies thérapeutiques prometteuses pour prévenir ou traiter la RPO dans la MC.
- Open Access
- 3 February 2026
- Published by Elsevier in Digestive and Liver Disease
- Vol. 58 (4) , 479-487
Association between physical activity with disease activity and functional disability in patients with inflammatory bowel disease
- 3 February 2026
- Published by Elsevier in Digestive and Liver Disease
- Vol. 58 (4) , 479-487
Open AccessAssociation between physical activity with disease activity and functional disability in patients with inflammatory bowel disease
- Open Access
- 13 January 2026
- Published by Georg Thieme Verlag KG in Endoscopy International Open
- Vol. 14 (CP) , a28841351
Artificial Intelligence-Based Localization of Small Bowel Anatomic Transition Zones in Crohn’s Disease Using Capsule Endoscopy
Background Small bowel (SB) capsule endoscopy (SBCE) is a key tool for Crohn’s disease (CD), but interpretation is time-consuming. Artificial intelligence (AI) could assist, yet automated SB segmentation, a prerequisite for analysis, may be challenging in patients with CD. Aims To evaluate an AI model detecting the pylorus and ileocolonic junction in CD SBCEs. Methods SBCE videos from 60 patients with CD were annotated by three readers. A ResNet-18 convolutional neural network classified frames into stomach, SB, or colon, with Viterbi-based anatomically constrained segmentation, using five-fold cross-validation. Accuracy was assessed by discrepancies relative to expert annotations. Univariate analysis explored associated factors. Expert review was conducted for poorly localized cases. Results The model was trained on 596,980 images, including 426,674 SB images. Median localization error was 2 frames (1 s) for the pylorus and 118.5 frames (~5 min) for the ileocolonic junction. In 26 videos (43.3%), the model localized both junctions with a temporal discrepancy <1 min compared with experts. In 53.3% of cases, AI detection of the ileocolonic junction preceded expert annotation by a median of 46 min, potentially leading to missed terminal ileal lesions. No factors were significantly associated with localization accuracy. Expert review highlighted inadequate cleanliness, capsule stagnation, and back-and-forth movements as main contributors to poor AI performance. Conclusions Our model successfully localizes both SB junctions in nearly half of SBCE videos from patients with CD. It consistently identifies the pylorus but shows modest performance at the ileocolonic junction. Capsule dynamics and bowel cleanliness remain major challenges for automated SB segmentation.
- 13 January 2026
- Published by Georg Thieme Verlag KG in Endoscopy International Open
- Vol. 14 (CP) , a28841351
Open AccessArtificial Intelligence-Based Localization of Small Bowel Anatomic Transition Zones in Crohn’s Disease Using Capsule Endoscopy
Background Small bowel (SB) capsule endoscopy (SBCE) is a key tool for Crohn’s disease (CD), but interpretation is time-consuming. Artificial intelligence (AI) could assist, yet automated SB segmentation, a prerequisite for analysis, may be challenging in patients with CD. Aims To evaluate an AI model detecting the pylorus and ileocolonic junction in CD SBCEs. Methods SBCE videos from 60 patients with CD were annotated by three readers. A ResNet-18 convolutional neural network classified frames into stomach, SB, or colon, with Viterbi-based anatomically constrained segmentation, using five-fold cross-validation. Accuracy was assessed by discrepancies relative to expert annotations. Univariate analysis explored associated factors. Expert review was conducted for poorly localized cases. Results The model was trained on 596,980 images, including 426,674 SB images. Median localization error was 2 frames (1 s) for the pylorus and 118.5 frames (~5 min) for the ileocolonic junction. In 26 videos (43.3%), the model localized both junctions with a temporal discrepancy <1 min compared with experts. In 53.3% of cases, AI detection of the ileocolonic junction preceded expert annotation by a median of 46 min, potentially leading to missed terminal ileal lesions. No factors were significantly associated with localization accuracy. Expert review highlighted inadequate cleanliness, capsule stagnation, and back-and-forth movements as main contributors to poor AI performance. Conclusions Our model successfully localizes both SB junctions in nearly half of SBCE videos from patients with CD. It consistently identifies the pylorus but shows modest performance at the ileocolonic junction. Capsule dynamics and bowel cleanliness remain major challenges for automated SB segmentation.
- Open Access
- 8 December 2025
- Published by Wolters Kluwer Health in Clinical and Translational Gastroenterology
- Vol. 17 (2) , e00954
Impact of Endometriosis on the Progression of Inflammatory Bowel Diseases: A Multicenter Retrospective Study
INTRODUCTION: Women with endometriosis have a higher risk of developing inflammatory bowel diseases (IBDs). This study aimed to better understanding the impact of endometriosis on the course of IBD. METHODS: We conducted a retrospective cohort study in 18 French and Belgian IBD centers between June 2022 and March 2023. Any patient with both conditions was eligible for inclusion. They were randomly matched to 1 or 2 patients with IBD without endometriosis. The impact on IBD progression was assessed using a composite severity criterion including intestinal damage or need for bowel surgery. RESULTS: Overall, 207 patients with both conditions (149 Crohn's disease [CD]; 58 ulcerative colitis [UC]) were matched to 409 patients with IBD alone. The median follow-up duration for IBD was 10 years (5.75–17). No difference was observed between the 2 groups regarding CD location, disease phenotype, and anoperineal involvement. Proctitis were more frequent in patients with UC and endometriosis. Patients with IBD with endometriosis were significantly less exposed to immunosuppressants (UC P < 0.01; CD P < 0.001) and biologics (UC P < 0.01; CD P < 0.001). Patients with CD with endometriosis had a less severe disease course compared with patients without endometriosis (hazard ratio 0.68, 95% confidence interval 0.50–0.92, P = 0.011). Patients with UC with endometriosis had not a significant different disease course compared with patients without endometriosis (hazard ratio 1.73, 95% confidence interval 0.74–4.00, P = 0.20). These results were similar in the subgroup of patients with endometriosis treated surgically. DISCUSSION: Endometriosis does not negatively influence the course of IBD, patients with CD even have a less severe progression. Patients were significantly less exposed to immunosuppressants and biologics.
- 8 December 2025
- Published by Wolters Kluwer Health in Clinical and Translational Gastroenterology
- Vol. 17 (2) , e00954
Open AccessImpact of Endometriosis on the Progression of Inflammatory Bowel Diseases: A Multicenter Retrospective Study
INTRODUCTION: Women with endometriosis have a higher risk of developing inflammatory bowel diseases (IBDs). This study aimed to better understanding the impact of endometriosis on the course of IBD. METHODS: We conducted a retrospective cohort study in 18 French and Belgian IBD centers between June 2022 and March 2023. Any patient with both conditions was eligible for inclusion. They were randomly matched to 1 or 2 patients with IBD without endometriosis. The impact on IBD progression was assessed using a composite severity criterion including intestinal damage or need for bowel surgery. RESULTS: Overall, 207 patients with both conditions (149 Crohn's disease [CD]; 58 ulcerative colitis [UC]) were matched to 409 patients with IBD alone. The median follow-up duration for IBD was 10 years (5.75–17). No difference was observed between the 2 groups regarding CD location, disease phenotype, and anoperineal involvement. Proctitis were more frequent in patients with UC and endometriosis. Patients with IBD with endometriosis were significantly less exposed to immunosuppressants (UC P < 0.01; CD P < 0.001) and biologics (UC P < 0.01; CD P < 0.001). Patients with CD with endometriosis had a less severe disease course compared with patients without endometriosis (hazard ratio 0.68, 95% confidence interval 0.50–0.92, P = 0.011). Patients with UC with endometriosis had not a significant different disease course compared with patients without endometriosis (hazard ratio 1.73, 95% confidence interval 0.74–4.00, P = 0.20). These results were similar in the subgroup of patients with endometriosis treated surgically. DISCUSSION: Endometriosis does not negatively influence the course of IBD, patients with CD even have a less severe progression. Patients were significantly less exposed to immunosuppressants and biologics.
- 20 October 2025
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 63 (1) , 57-69
Clinical Trial: Simplified Bowel Preparation for Small Bowel Capsule Endoscopy in Crohn's Disease
Background: Small bowel (SB) capsule endoscopy (SBCE) is a key tool in patients with Crohn's disease (CD). Optimal bowel preparation remains debated. Aims: To compare the efficacy of a simplified preparation (clear liquid diet with 500 mL of water pre‐ and 1 L post‐capsule ingestion) to a polyethylene glycol (PEG)‐based preparation (24 h‐residue‐free diet with 2 L of PEG) in patients with established CD. Methods: In this randomised, controlled, single‐blind, superiority, multicentre trial, patients were assigned 1:1 to either the simplified preparation or the PEG‐based preparation. Intestinal cleanliness (quantified by the KODA score and qualitatively evaluated), patient acceptability, diagnostic yield, capsule completion rate, and SB transit time (SBTT) were compared between groups. Results: With 142 SBCE, we observed no difference in intestinal cleanliness. Patients' acceptability of preparation and SBCE procedure was significantly higher with the simplified preparation. Diagnostic yield was similar, as well as the capsule completion rate and SBTT. The area under the receiver operating characteristic curve of the KODA score was 0.87 (95% CI: 0.84–0.90). Using a threshold of 2.25, the score allowed us to discriminate images with ‘good’ and ‘fair or poor’ cleanliness with accuracy, sensitivity, and specificity of 80%, 76%, and 84%, respectively. Conclusions: A simplified preparation consisting of a clear liquid diet and water is a viable alternative to a PEG‐based preparation prior to SBCE in patients with CD, offering comparable SB cleanliness and diagnostic outcomes while improving acceptability. Trial Registration: ClinicalTrials.gov identifier: NCT05117996 and the article was written in line with the Consolidated Standards of Reporting Trials (CONSORT) checklist
- 20 October 2025
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 63 (1) , 57-69
Clinical Trial: Simplified Bowel Preparation for Small Bowel Capsule Endoscopy in Crohn's Disease
Background: Small bowel (SB) capsule endoscopy (SBCE) is a key tool in patients with Crohn's disease (CD). Optimal bowel preparation remains debated. Aims: To compare the efficacy of a simplified preparation (clear liquid diet with 500 mL of water pre‐ and 1 L post‐capsule ingestion) to a polyethylene glycol (PEG)‐based preparation (24 h‐residue‐free diet with 2 L of PEG) in patients with established CD. Methods: In this randomised, controlled, single‐blind, superiority, multicentre trial, patients were assigned 1:1 to either the simplified preparation or the PEG‐based preparation. Intestinal cleanliness (quantified by the KODA score and qualitatively evaluated), patient acceptability, diagnostic yield, capsule completion rate, and SB transit time (SBTT) were compared between groups. Results: With 142 SBCE, we observed no difference in intestinal cleanliness. Patients' acceptability of preparation and SBCE procedure was significantly higher with the simplified preparation. Diagnostic yield was similar, as well as the capsule completion rate and SBTT. The area under the receiver operating characteristic curve of the KODA score was 0.87 (95% CI: 0.84–0.90). Using a threshold of 2.25, the score allowed us to discriminate images with ‘good’ and ‘fair or poor’ cleanliness with accuracy, sensitivity, and specificity of 80%, 76%, and 84%, respectively. Conclusions: A simplified preparation consisting of a clear liquid diet and water is a viable alternative to a PEG‐based preparation prior to SBCE in patients with CD, offering comparable SB cleanliness and diagnostic outcomes while improving acceptability. Trial Registration: ClinicalTrials.gov identifier: NCT05117996 and the article was written in line with the Consolidated Standards of Reporting Trials (CONSORT) checklist
- Open Access
- 28 August 2025
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 121 (7) , 1701-1710
Subcutaneous Infliximab for Perianal Crohn's Disease: The BioLap-Rem Multicenter Study From the GETAID
INTRODUCTION: Intravenous infliximab (IFX) is the cornerstone for treating patients with perianal Crohn's disease (pCD). Data on the recently launched subcutaneous (SC) IFX for pCD are limited. The aim of our study was to evaluate the effectiveness and safety of SC IFX in pCD. METHODS: We conducted a multicenter retrospective cohort study from the GETAID, including patients with either active (group 1) or inactive (group 2) pCD when they started SC IFX. Inclusion criteria were, for group 1: active pCD in the 6 months before initiation of SC IFX; for group 2: inactive pCD for >6 months at the time of IV to SC switch. The primary end points were clinical remission at 6 months in group 1 and pCD relapse in group 2. RESULTS: Of the 183 patients included in 24 centers, 66 were in group 1 and 117 in group 2. The median follow-up was 50.4 (27.0–64.6) and 53.4 (40.6–67) weeks, respectively. In group 1 at 6 months, clinical remission was observed in 44.6% of patients and clinical response in 87.7%. Clinical remission including seton removal occurred in 35.5% of patients. In multivariable analysis, high body mass index was the only independent predictor of remission (odds ratio 0.88, 95% confidence interval 0.77–0.99). In group 2, rates of relapse-free survival were 94.3% and 87.9% at 6 and 12 months, respectively. Sixteen cases (8.3%) of adverse events related to SC injection were observed. DISCUSSION: SC IFX was effective and safe for the treatment of active pCD and for maintaining remission after switching in this large multicenter cohort, thus supporting its use in routine practice in this indication.
- 28 August 2025
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 121 (7) , 1701-1710
Open AccessSubcutaneous Infliximab for Perianal Crohn's Disease: The BioLap-Rem Multicenter Study From the GETAID
INTRODUCTION: Intravenous infliximab (IFX) is the cornerstone for treating patients with perianal Crohn's disease (pCD). Data on the recently launched subcutaneous (SC) IFX for pCD are limited. The aim of our study was to evaluate the effectiveness and safety of SC IFX in pCD. METHODS: We conducted a multicenter retrospective cohort study from the GETAID, including patients with either active (group 1) or inactive (group 2) pCD when they started SC IFX. Inclusion criteria were, for group 1: active pCD in the 6 months before initiation of SC IFX; for group 2: inactive pCD for >6 months at the time of IV to SC switch. The primary end points were clinical remission at 6 months in group 1 and pCD relapse in group 2. RESULTS: Of the 183 patients included in 24 centers, 66 were in group 1 and 117 in group 2. The median follow-up was 50.4 (27.0–64.6) and 53.4 (40.6–67) weeks, respectively. In group 1 at 6 months, clinical remission was observed in 44.6% of patients and clinical response in 87.7%. Clinical remission including seton removal occurred in 35.5% of patients. In multivariable analysis, high body mass index was the only independent predictor of remission (odds ratio 0.88, 95% confidence interval 0.77–0.99). In group 2, rates of relapse-free survival were 94.3% and 87.9% at 6 and 12 months, respectively. Sixteen cases (8.3%) of adverse events related to SC injection were observed. DISCUSSION: SC IFX was effective and safe for the treatment of active pCD and for maintaining remission after switching in this large multicenter cohort, thus supporting its use in routine practice in this indication.
- Open Access
- 5 August 2025
- Published by Elsevier in Clinics and Research in Hepatology and Gastroenterology
- Vol. 49 (8) , 102665
Improving fecal sample collection in patients with inflammatory bowel disease: A comparative evaluation of two calprotectin devices
- 5 August 2025
- Published by Elsevier in Clinics and Research in Hepatology and Gastroenterology
- Vol. 49 (8) , 102665
Open AccessImproving fecal sample collection in patients with inflammatory bowel disease: A comparative evaluation of two calprotectin devices